Captor Therapeutics Spolka Akcyjna (CTX) Stock Overview
A biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Captor Therapeutics Spolka Akcyjna Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł80.40 |
| 52 Week High | zł89.20 |
| 52 Week Low | zł31.20 |
| Beta | 0.73 |
| 1 Month Change | -3.60% |
| 3 Month Change | 24.07% |
| 1 Year Change | 93.27% |
| 3 Year Change | -43.97% |
| 5 Year Change | n/a |
| Change since IPO | -53.25% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation
Mar 28
Here's Why We're Not Too Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation
Jul 13We Think Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Drive Business Growth
Mar 10We're Not Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn
Oct 03Here's Why We're Not At All Concerned With Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation
Mar 13Companies Like Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Invest In Growth
Jun 15Shareholder Returns
| CTX | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -8.0% | -0.1% | 0.05% |
| 1Y | 93.3% | -3.1% | 18.0% |
Return vs Industry: CTX exceeded the Polish Biotechs industry which returned -3% over the past year.
Return vs Market: CTX exceeded the Polish Market which returned 20.8% over the past year.
Price Volatility
| CTX volatility | |
|---|---|
| CTX Average Weekly Movement | 5.6% |
| Biotechs Industry Average Movement | 5.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 11.3% |
| 10% least volatile stocks in PL Market | 3.3% |
Stable Share Price: CTX has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: CTX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 91 | Michal Walczak | www.captortherapeutics.com |
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow; and CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor.
Captor Therapeutics Spolka Akcyjna Fundamentals Summary
| CTX fundamental statistics | |
|---|---|
| Market cap | zł444.51m |
| Earnings (TTM) | -zł40.71m |
| Revenue (TTM) | zł7.57m |
Is CTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTX income statement (TTM) | |
|---|---|
| Revenue | zł7.57m |
| Cost of Revenue | zł2.63m |
| Gross Profit | zł4.95m |
| Other Expenses | zł45.66m |
| Earnings | -zł40.71m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.36 |
| Gross Margin | 65.32% |
| Net Profit Margin | -537.79% |
| Debt/Equity Ratio | 0% |
How did CTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 06:59 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Captor Therapeutics Spolka Akcyjna is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Marcin Nowak | Ipopema Securities S.A. |